SUMMARY
Propofol is a very commonly used anaesthetic agent but is known to cause pain on injection in 40 to 92% cases, especially when injected into a vein on the dorsum of the hand [1] [2] [3] [4] [5] [6] . A large number of methods have been used to try to decrease the incidence of this pain with variable success (e.g. use of a larger vein 6, 7 , aspiration of blood in propofol syringe before injection 8 , cooling 9 or diluting 10 the propofol solution, mixing lignocaine with propofol in the same syringe 5, 11, 12 , or pre-treatment with lignocaine or procaine 13 , ondansetron 14 , metoclopramide 15 , opioids 1,2 , magnesium sulphate 16 and ketorolac 4 ). Various theories have been suggested to explain the cause of propofol injection pain 3, 17 . Recently kallikrein-kinin cascade has been implicated, which is triggered by release of kininogen from the vein wall following drug injection 7 . The action of products of this cascade on the nociceptors may be enhanced by prostaglandins 18 . Non-steroidal anti-inflammatory drugs (NSAIDS) reduce prostaglandin synthesis via their inhibition of cyclo-oxygenase. One such drug, ketorolac, has been tried with good results 4 . Diclofenac, another NSAID that is often used for postoperative pain relief, is one of the strongest cyclooxygenase inhibitors 19 . As we use diclofenac routinely in our patients unless contraindicated, we decided to study the efficacy of diclofenac for this purpose. Hence the present study was planned with the aim of investigating the effect of pretreatment with intravenous diclofenac on pain during propofol injection.
MATERIALS AND METHODS
One hundred and twenty patients, aged 16 years and above, belonging to ASA physical status 1 or 2, undergoing elective surgery were included in this double-blind, prospective and randomized study. The study was approved by our institutional ethics committee and written informed consent was obtained from each patient or guardian. Patients were excluded if they were taking regular analgesics, had a known sensitivity to NSAID or propofol, had a coagulation disorder, a history of gastrointestinal bleeding, asthma, hepatic or renal impairment, or required rapid sequence induction. Patients were randomly allocated by draw of lots to one of the three equal groups to receive diclofenac 25 mg (group D25), diclofenac 15 mg (group D15) or normal saline (group NS) as pretreatment solutions. Group NS acted as a control group.
All the patients were premedicated with diazepam 5-10 mg on the night before surgery and 5 mg on the morning of surgery. In the operating theatre, after instituting routine monitoring, an 18 gauge cannula was inserted without local infiltration on the dorsum of the right hand of the patient and a Ringer's lactate infusion started at the rate of 5 to 6 ml/min. Patients in D25 group and D15 group received diclofenac 25 mg or 15 mg IV respectively, each diluted to 5 ml with normal saline. Those in control, i.e. NS group received 5 ml of normal saline. The study drugs were injected in a running drip over a period of 10 seconds. Thirty seconds after completion of this injection, 25% of the calculated propofol dose for the patient was injected at a rate of 0.5 ml/s. Pain was assessed after the injection of the study drug as well as after propofol by another anaesthetist who was blinded to the study solution. Patients were also blinded to their group allocation. The severity of pain was defined according to pain scores advocated by McCrirrick and Hunter 20 ( Table 1 ). The same scoring system was used to assess pain following injection of both propofol and the study drug. The induction was then continued with the remaining propofol, followed by morphine and vecuronium. As the analgesic dose of diclofenac is 1 mg/kg, the remainder of this dose was administered before the end of the procedure.
Adverse venous sequelae were defined as appearance of any redness, tenderness, hardness or cord-like sensation over the cannulated vein. The patients were followed up everyday in the ward to detect any such sequelae till the time of their discharge.
As venous sequelae were present in some patients in each group, the methodology was modified after doing 75 cases. To exclude the effect of other drugs in the last 45 cases, another cannula was inserted in the left hand following induction of anaesthesia, which was subsequently used for all other drug and fluid administrations. The cannula used for the study was removed in the postoperative room. These patients were similarly followed up for venous sequelae on the dorsum of the right hand.
Based on previous studies [1] [2] [3] [4] [5] , we estimated the incidence of pain in patients receiving placebo to be around 70%. A reduction in the incidence by 50% was considered clinically significant. The sample size required to detect a 50% reduction at 5% level of significance with 90% power was 32 patients per group. Therefore inclusion of 40 patients in each group was considered appropriate.
A Chi-squared test was used to compare the incidence of propofol injection pain in the three groups with Bonferroni's adjustment applied for further intergroup analysis. Diclofenac pain was compared using Fisher's exact test. P<0.05 was considered significant.
RESULTS
The three groups were similar with respect to age, weight and sex distribution ( Table 2 ). Nineteen patients in D25 and 12 in D15 group experienced no pain following administration of propofol as compared to 10 in control group (Table 3) . The difference was statistically not significant (P=0.084). The incidence of moderate to severe pain in the three groups was also compared. Six patients (15%) in D25 and 10 patients (25%) in D15 group complained of moderate to severe pain, whereas 19 patients (47.5%) experienced moderate to severe pain in the control group. The reduction in incidence of moderate to severe pain during propofol injection was found to be significant after pretreatment with either diclofenac 25 mg (P=0.0017) or diclofenac 15 mg (P=0.0363) (when compared to the control group). However the two diclofenac groups did not differ from each other in this regard (P=0.2635). Mild pain was reported by four patients in group D25 and five in group D15 after the injection of diclofenac itself. However, there was no spontaneous complaint of this type of pain and it could be elicited only after specific questioning. The incidence of this diclofenac induced pain was statistically similar in the two groups (P=0.50).
In 75 patients, the same cannula was used to administer all the drugs and fluids. The incidence of venous sequelae in these patients was 8/28, 6/22 and 7/25 in the D25, D15 and control groups respectively. Out of 45 patients in whom a separate cannula was used for administration of study drugs, 12 belonged to D25 group, 18 to D15 group and 15 to control group. None of these patients had any complaints suggestive of venous sequelae.
DISCUSSION
Pretreatment with diclofenac in doses of 25 mg and 15 mg was found to be effective in reducing the incidence of moderate to severe pain following propofol injection. The incidence of pain during propofol injection in our control group in this study was 75%.
The onset of propofol injection pain is usually not immediate. This suggests involvement of an enzyme cascade, probably the plasma kallikrein-kinin system 7 . Pretreatment with nafamostat mesilate, a kallikrein inhibitor, prevented injection pain, thus supporting the above hypothesis 21 . As prostaglandins modulate local pain by modifying the nociceptor response to the products of kinin cascade 18 , NSAIDs injected intravenously should be able to reduce propofol injection pain by inhibiting prostaglandin synthesis pathways in the vein wall 22 . Aspirin 15 mg prior to propofol injection resulted in significant reduction in such pain 23 . Huang et al 4 , using ketorolac in combinations of different doses and occlusion times, found that ketorolac 10 mg with venous occlusion for 120 s or ketorolac 15 mg or 30 mg intravenously without occlusion reduced the pain of propofol injection.
Diclofenac is another potent inhibitor of cyclo-oxygenase. It also reduces intracellular concentration of free arachidonic acid in leucocytes, perhaps by altering the release or uptake of fatty acid 19 . Both mechanisms act to inhibit prostaglandin synthesis. There have been no previous reports of the use of diclofenac for this purpose. Therefore we decided to evaluate the effect of two different doses of diclofenac on pain during propofol injection. Intravenous diclofenac in a dose of 25 mg is known to induce maximum inhibition of prostaglandin synthesis and is regarded as the ceiling dose 24 . Therefore 25 mg and 15 mg were selected as pretreatment doses.
Moderate to severe pain at the time of injection is considered to be clinically unacceptable 25 , as it can cause agitation and hinder the smooth induction of anaesthesia 1 . Therefore we analysed the differences in incidence of moderate to severe pain in the three groups. Both doses of diclofenac pretreatment used in this study, i.e. 25 mg and 15 mg were successful in reducing the incidence of moderate to severe pain when compared to control group. The primary aim of this study was not to compare different doses of diclofenac. But as this was a preliminary study and no reference regarding the dose of diclofenac for this purpose was available, two different doses were compared with the control group.
Diclofenac is contraindicated or should be used with caution in patients with gastrointestinal bleeding/ulceration, asthma, coagulopathies, sensitivity to NSAIDs and impairment of hepatic or renal function. All such patients were excluded from the present study, and for the same reason care should be taken to rule out the above conditions before using diclofenac pre-treatment.
The efficacy of diclofenac pretreatment in our study is comparable to that of ketorolac pretreatment used by Huang and co-workers 4 . Moderate to severe pain (pain scores 2 and 3) in our study decreased from 47.5% in the control group to 25% in D15 group and 15% in D25 group. Huang and co-workers studied the effect of different doses of ketorolac pretreatment with different venous occlusion times. They graded propofol injection pain as 0 (no pain), 1 (discomfort), 2 (pain) and 3 (severe pain). The incidence of grade 2 and 3 pain in their study was 46.7% in their control group, which decreased to 20% and 10% in patients receiving ketorolac 15 mg and 30 mg respectively. Propofol was injected after 60 seconds of ketorolac pretreatment without venous occlusion in these patients. Ketorolac 10 mg with venous occlusion for 120 seconds was also able to reduce the incidence of propofol injection pain to 16.7%.
An important advantage of diclofenac over ketorolac is its cost-effectiveness. In India, the cost of ketorolac (IV) is more than twice that of diclofenac (IV) for equipotent doses.
Lignocaine has been used as pretreatment or mixed with propofol to prevent propofol injection pain 1, 7, 13, 15 . Lignocaine 10 mg given 15 seconds before injection of propofol reduces the incidence of pain to 35% from 51% 13 . In a study by Scott and colleagues 7 , two out of 15 patients complained of propofol injection pain after receiving 1% lignocaine 1 ml mixed with propofol compared with 7 out of 15 patients receiving propofol bolus only. Lyons and colleagues stressed the need to prevent severe pain. In their study 24% patients receiving lignocaine 10 mg pretreatment complained of moderate to severe pain as against 44% patients receiving saline. The incidence of severe pain was reported to be 4% in their lignocaine group. In our study with diclofenac the incidence of severe pain was 2.5% and 5% in D25 and D15 groups respectively, suggesting similar efficacy for this purpose.
In our initial 75 cases all the drugs and fluids, including antibiotics, were administered through the same cannula in the intra-operative as well as postoperative period. These drugs are known to have an incidence of venous thrombophlebitis. Therefore venous sequelae in these patients could be attributed to the drugs and fluids injected through the same cannula, as no signs suggestive of venous irritation were seen in patients in whom a dedicated venous cannula was used for the study.
Intravenous injection of diclofenac in its undiluted form is associated with an unacceptably high incidence of venous sequelae within 72 hours after intravenous injection (with a 60-80% incidence of venous thrombosis) 26 . Venous irritation can be reduced by a five-fold dilution in saline or dextrose or slow injection 27 or it can be entirely avoided if given as a slow infusion 28 . In our study, diclofenac was diluted in saline at least five-fold. Moreover, it was administered in a running drip leading to further dilution of the drug. Probably this was responsible for the absence of any venous sequelae in patients in whom a separate cannula was used to administer the study drugs.
The effect of ketorolac for reduction of propofol injection pain has been seen to improve by increasing the venous occlusion time 4 . Other authors have also recommended longer time intervals between pretreatment drug and propofol injection to get better results 22 . We did not occlude the vein at the time of diclofenac injection, and preferred to give it in a running drip because of its irritant properties as described earlier. However, increasing the time interval between diclofenac and propofol injections may help to further reduce the propofol injection pain.
On specific questioning, four patients in D25 group and five patients in D15 group complained of mild pain following diclofenac injection. Injection pain has been described following intramuscular use of this drug 29 but we could not find any studies reporting pain on intravenous injection of diclofenac. This drug's poor aqueous solubility and susceptibility to oxidation necessitate the use of co-solvents and antioxidants 24 which could have been responsible for this side-effect in our patients. The absence of pain in other studies could be due to a greater dilution of diclofenac as it was used as an infusion in most cases 30, 31 . The efficacy of the two doses in our study being statistically similar, further dilutions of diclofenac 15 mg to a larger volume should be tried in order to prevent this side-effect. Seymour et al 24 administered bolus doses of up to 75 mg of diclofenac intravenously. They described the diclofenac injection used by them as "a new preparation" but the chemical composition was not mentioned.
Lignocaine, the drug commonly used for alleviation of propofol injection pain, is effective but it is not successful in 100% of cases 1, 7, 13 . Therefore the search for newer agents for this purpose continues. We did not attempt to compare lignocaine and diclofenac in this study, but based on previous studies, diclofenac does not seem to be superior to lignocaine for this purpose. Moreover, diclofenac has an incidence of mild pain on injection, which has not been reported with lignocaine. Further studies are required to compare lignocaine and diclofenac, and also to determine if diclofenac-induced pain can be reduced by using the drug in a greater dilution.
To conclude, intravenous diclofenac in a dose of 15 mg or 25 mg, diluted to 5 ml volume, administered 30 seconds before propofol injection reduces the incidence of moderate to severe pain associated with propofol, but itself can lead to mild pain in some patients. Thus use of diclofenac in the above dilution does not appear to be a suitable pre-treatment for propofol injection pain. However, further studies are warranted to investigate the effects of greater dilutions of diclofenac and longer time intervals between diclofenac and propofol injection.
